TianShiLi quarter net profit attributable to the parent company owners 22.3 billion, MBT Kisumu2 a year-on-year growth 138.79%, corresponding EPS to 0.31 yuan.
Investment points:
1 quarter operating performance relatively good. This year 1-3 months to achieve the company revenue reached 1.373 billion, an increase of 38.13%; The net profit attributable to the parent company owners 22.3 billion, 138.79% year-on-year. Sell tianjin business remit deduction about 627 million shares, net profit after-tax net income factors about 45%, sales year-on-year rise, and significant financial expenses drastically reduced; .. The pharmaceutical industry, business growth, are obviously ascension. Pharmaceutical industry, quarter leading varieties in basic-level demand dropping compound danshen authentication driven with the FDA peatlands and is expected to reach a value of about 20% MBT Fumba growth in global, 11 end will start FDA3 stage clinical trials. Second-line products, raise serum brain particles, water LinJia and yiqi complex veins is a fast growth of plenty licensing injection, etc, the next three quarters will keep growing rapidly. Pharmaceutical business is expected to more than 40 percent year-on-year growth in gross margins remain stable; .. Flu vaccine may be expected as the second half new contribution income. Treatment mild-to-moderate cerebral infarction of salvia miltiorrhiza polyphenols acid and used for acute st-segment elevation myocardial infarction urokinase recombinant human has won the administration's approval before the new drugs, expected in August 7 - urokinase through GMP acceptance, and the unit flu vaccine, which is expected to three new product will soon start selling; the second half Maintain strongly recommend rating. Compound danshen pill that future will continue to benefit from the FDA, raise serum authentication promote brain particles second-line product rapid growth not decreased, product is about to begin harvest, group chemical medicine assets, such as injection may further determines the growth prospects. We expect the company 11-13 years of EPS 1.59 1.32, respectively, compared with $1.95 respectively, 20% and 23% growth 51%, maintain the strongly recommend investment rating.
Risk hint: compound danshen dropping very big, company's overall performance cardinal maintain mbt shoes uk high growth has the certain difficulty. (
Investment points:
1 quarter operating performance relatively good. This year 1-3 months to achieve the company revenue reached 1.373 billion, an increase of 38.13%; The net profit attributable to the parent company owners 22.3 billion, 138.79% year-on-year. Sell tianjin business remit deduction about 627 million shares, net profit after-tax net income factors about 45%, sales year-on-year rise, and significant financial expenses drastically reduced; .. The pharmaceutical industry, business growth, are obviously ascension. Pharmaceutical industry, quarter leading varieties in basic-level demand dropping compound danshen authentication driven with the FDA peatlands and is expected to reach a value of about 20% MBT Fumba growth in global, 11 end will start FDA3 stage clinical trials. Second-line products, raise serum brain particles, water LinJia and yiqi complex veins is a fast growth of plenty licensing injection, etc, the next three quarters will keep growing rapidly. Pharmaceutical business is expected to more than 40 percent year-on-year growth in gross margins remain stable; .. Flu vaccine may be expected as the second half new contribution income. Treatment mild-to-moderate cerebral infarction of salvia miltiorrhiza polyphenols acid and used for acute st-segment elevation myocardial infarction urokinase recombinant human has won the administration's approval before the new drugs, expected in August 7 - urokinase through GMP acceptance, and the unit flu vaccine, which is expected to three new product will soon start selling; the second half Maintain strongly recommend rating. Compound danshen pill that future will continue to benefit from the FDA, raise serum authentication promote brain particles second-line product rapid growth not decreased, product is about to begin harvest, group chemical medicine assets, such as injection may further determines the growth prospects. We expect the company 11-13 years of EPS 1.59 1.32, respectively, compared with $1.95 respectively, 20% and 23% growth 51%, maintain the strongly recommend investment rating.
Risk hint: compound danshen dropping very big, company's overall performance cardinal maintain mbt shoes uk high growth has the certain difficulty. (
No comments:
Post a Comment